GENBA PHARMA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 1,256,448 | 1,575,594 | 1,688,164 | 2,103,782 | 2,699,141 | 3,233,617 | 3,505,113 | 3,761,607 |
| Profit before tax | 191,234 | 331,927 | 470,571 | 525,948 | 825,735 | 984,963 | 986,489 | 1,063,172 |
| Net profit | 163,919 | 283,442 | 400,612 | 446,987 | 705,256 | 838,917 | 844,627 | 895,650 |
| Equity | 557,841 | 723,932 | 1,007,341 | 1,096,466 | 1,331,135 | 1,670,051 | 1,814,678 | 2,010,329 |
| Liabilities | 127,335 | 254,026 | 179,735 | 308,573 | 538,168 | 372,908 | 640,956 | 408,193 |
| Non-current assets | 71,329 | 55,059 | 38,877 | 29,405 | 128,564 | 142,918 | 133,428 | 98,367 |
| Current assets | 610,662 | 920,563 | 1,142,138 | 1,372,467 | 1,736,073 | 1,889,416 | 2,314,367 | 2,313,578 |
| Total assets | 681,991 | 975,622 | 1,181,015 | 1,401,872 | 1,864,637 | 2,032,334 | 2,447,795 | 2,411,945 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 674,325 | 727,387 | 760,486 |
| Social insurance contributions | - | - | - | - | - | 68,800 | 85,069 | 86,603 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +25.5% | +25.4% | +7.1% | +24.6% | +28.3% | +19.8% | +8.4% | +7.3% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 24.0% | 29.1% | 33.9% | 31.9% | 37.8% | 41.3% | 34.5% | 37.1% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 29.4% | 39.2% | 39.8% | 40.8% | 53.0% | 50.2% | 46.5% | 44.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 13.0% | 18.0% | 23.7% | 21.2% | 26.1% | 25.9% | 24.1% | 23.8% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 15.2% | 21.1% | 27.9% | 25.0% | 30.6% | 30.5% | 28.1% | 28.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.2 | 0.4 | 0.2 | 0.3 | 0.4 | 0.2 | 0.4 | 0.2 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 193,300 | 252,095 | 247,050 | 277,423 | 368,066 | 404,202 | 368,959 | 389,130 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
GENBA PHARMA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-01-16 | 2026-01-21 | 0.24 |
| 2022-03-16 | 2022-03-16 | 52.07 |
GENBA PHARMA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2024-12-30 | 2024-12-30 | 43064.47 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
GENBA PHARMA, UAB (code 303395484) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In 2025, the company generated revenue of EUR 3.76 million, up 7.3% year on year and 16.3% over two years. Net profit reached EUR 895.6 thousand, following EUR 844.6 thousand in 2024 and EUR 838.9 thousand in 2023, which shows a steady upward trend in earnings. The profit margin remained strong at 23.8% in 2025, compared with 24.1% in 2024 and 25.9% in 2023. The balance sheet showed total assets of EUR 2.41 million, equity of EUR 2.01 million and liabilities of EUR 408.2 thousand. The equity ratio stood at 83.3% and debt-to-equity at 0.20, indicating a conservative capital structure. Asset turnover was 1.56x, ROE 44.5% and ROA 37.1%. Revenue per employee was EUR 418.0 thousand, and profit per employee EUR 99.5 thousand, reflecting high productivity.